Ovarian cancer vaccine - MabVax/MSKCC

Drug Profile

Ovarian cancer vaccine - MabVax/MSKCC

Alternative Names: MV-Ovar; NSC-748933; Polyvalent vaccine-KLH conjugate - MabVax

Latest Information Update: 10 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Gynecologic Oncology Group; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer

Most Recent Events

  • 10 Jun 2015 Phase-II development in Ovarian cancer is ongoing in the US
  • 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
  • 28 May 2013 Memorial Sloan-Kettering Cancer Center completes enrolment in its phase II trial for Ovarian cancer in USA (NCT00857545)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top